Celltrion Healthcare receives European Commission (EC) approval for the first high concentration, low-volume and citrate-free biosimilar adalimumab, Yuflyma TM (CT-P17)
Celltrion Healthcare today announced that on February 11th, the European Commission (EC) has granted marketing authorisation for Yuflyma™ (CT-P17), an adalimumab biosimilar, across all thirteen intended indications for the treatment of multiple chronic inflammatory diseases.
The EC approval of Yuflyma™ follows the recommendation for marketing authorisation issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in December 2020. The marketing authorisation is based on analytical, preclinical and clinical studies, demonstrating that Yuflyma™ is comparable to adalimumab, the reference product, in terms of safety, efficacy, PK/PD and immunogenicity up to 24 weeks1 and 1 year2 following treatment. Based on the results of the pivotal study, a high concentration formulation of Yuflyma™ has been approved for use in the European Union (EU), in patients with thirteen chronic inflammatory diseases; rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), axial spondyloarthritis without radiographic evidence of AS (nr-axSpA), psoriatic arthritis (PsA), psoriasis (PsO), paediatric plaque psoriasis (pPsO), hidradenitis suppurativa (HS), Crohn’s disease (CD), paediatric Crohn’s disease (pCD), ulcerative colitis (UC), uveitis (UV) and paediatric uveitis (pUV).
“In Europe, according to IQVIA data, 60% of the whole adalimumab market has been taken by high concentration formulation and over 90% of the original adalimumab market has already been replaced with a high concentration version. With high concentration, low-volume, and consequently less pain, adalimumab can improve treatment adherence at the very least. Therefore, we focused on development of a high concentration biosimilar to provide a significant alternative to the adalimumab treatment category,” said Dr. HoUng Kim, Ph.D., Head of Medical and Marketing Division at Celltrion Healthcare. “In terms of the administration device, we have looked to ensure improved convenience for patients as well as providers with the inclusion of needle size (29G), latex-free to reduce allergy risk, and a long storage period or shelf life at room temperature for 30 days.”
Professor Rieke Alten, Head of the Department of Internal Medicine, Rheumatology, Clinical Immunology and Osteology at Schlosspark-Klinik, Teaching Hospital of Charité, Berlin, Germany said, “Over the past two decades, anti-tumour necrosis factor (TNF) biologics have revolutionised the management of chronic immune-mediated inflammatory diseases, but some of the features needed improvement for patients to reach their therapeutic goals. As a physician, we welcome these value-added features such as high concentration and low-volume formulations to reduce injection discomfort.”
The centralised marketing authorisation granted by the EC is valid in all EU Member States as well as in the European Economic Area countries Iceland, Liechtenstein and Norway. This announcement will enable affordable access to a high concentration adalimumab biosimilar, broadening treatment alternatives for patients suffering with chronic inflammatory disease including rheumatoid arthritis, psoriasis, Crohn’s disease and ulcerative colitis.
Celltrion will take the EC Decision Reliance Procedure (ECDRP) to minimise lead time to launch the product in the UK and remains committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies.
- ENDS -
Notes to Editors:
About CT-P17 (biosimilar adalimumab)
CT-P17 is the first proposed high concentration, low- volume and citrate-free adalimumab biosimilar. CT-P17 is indicated for the treatment of patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), axial spondyloarthritis without radiographic evidence of AS (nr-axSpA), psoriatic arthritis (PsA), psoriasis (Ps), paediatric plaque psoriasis (pPs), hidradenitis suppurativa (HS), Crohn’s disease (CD), paediatric Crohn’s disease (pCD), ulcerative colitis (UC), uveitis (UV) and paediatric uveitis (pUV). CT-P17 is a recombinant human monoclonal antibody that contains the active ingredient adalimumab. Adalimumab is a fully human anti–tumour necrosis factor α (anti-TNFα) monoclonal antibody. CT-P17 provides pain-reducing features as it comes with citrate-free formulation, meaning it causes less pain upon injection.
About Celltrion Healthcare
Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information please visit: https://www.celltrionhealthcare.com/en-us
1 J. Kay., et al. (2020). A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of a Proposed High Concentration (100 mg/mL) Adalimumab Biosimilar (CT-P17) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis. Poster Presented at ACR Convergence 2020
2 Data on file
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
1010data Partners with Strategix CFT to Enhance the Value of Retailer Data and Expand European Coverage9.3.2021 11:00:00 CET | Press release
1010data, a provider of analytical intelligence and data sharing solutions to the retail, consumer goods and financial services markets, and Strategix CFT, a boutique consulting company that specializes in innovative retail technologies and comprehensive systems integration, announced today that they have entered into a strategic partnership to provide offerings that deliver enhanced customer insights. Targeted at Retailers and Consumer Packaged Goods (CPG) companies across the UK and Europe, the two companies will use their combined resources to develop analytics solutions that deliver the fastest predictive and prescriptive customer insights. The new partnership will provide advanced data analytics technology driving best practices for large retailers to optimize and grow their business in this fast-changing market environment. This will include a single, powerful source of data enabling collaborative planning between retailers and suppliers. A single, integrated analytics platform e
Scoro Raises $16 Million in Series B Funding To Invest In Its End-to-End Work Management Software9.3.2021 11:00:00 CET | Press release
Scoro, an award-winning work management software for professional service businesses, has closed a $16.4 million Series B funding round led by Kennet Partners. Additional investors include Columbia Lake Partners, Inventure, Livonia Partners and Tera Ventures. The investment will fuel continued global expansion and is supported by new French and Spanish versions of the software. “Even before Covid-19 hit, most professional service businesses used as many as a dozen different platforms daily,” said Scoro’s Founder and CEO, Fred Krieger. “However, teams now realise that constantly switching between tools harms productivity and results in lost data and duplicated work. In many ways, these tools became weapons of mass distraction. We’re proud to have the support of Kennet Partners and other investors as we help businesses identify and remove these weapons of mass distraction with our end-to-end work management software.” Scoro's most recent product launch has been a modernization of the Gan
XPRIZE and Cognizant Announce Grand Prize Winners in Pandemic Response Challenge to Restart Economies Around the World9.3.2021 09:31:00 CET | Press release
XPRIZE, the world’s leader in designing and operating incentive competitions to solve humanity’s grand challenges, in partnership with Cognizant(Nasdaq: CTSH), one of the world's leading technology and professional services companies, today announced the Grand Prize Winners in the $500K Pandemic Response Challenge. The four-month global competition was designed to harness the power of data and artificial intelligence in equipping policymakers, health officials and business leaders with the insights and guidance necessary to implement public safety measures that help keep local economies open while minimizing virus outbreaks as vaccines become more widely available. These decision-makers are encouraged to use the results, methodologies and technology from the challenge as reference on approaches to minimize potential outbreaks, now and moving forward. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210309005419/en/ Winning fir
The NAGA Group AG Closes USD 30 Million Financing Framework and Reports Record Growth9.3.2021 09:23:00 CET | Press release
The NAGA Group AG (XETRA: N4G, ISIN: DE000A161NR7), provider of the social network for financial market trading NAGA.com, reports on the largest financing arrangement in the company's history to date and further record growth in February 2021. NAGA has signed an agreement with the US Fund Yorkville Advisors securing a growth financing framework of up to USD 30 million. "We are excited about the deal with Yorkville and are setting the course for NAGA to scale even faster. The financing gives us the power and the flexibility to allow the company to be taken to the next level. NAGA is a growth case in a very large and rapidly growing market. This decade will be definitely the breakthrough period for FinTechs", comments NAGA CEO Benjamin Bilski on the closed deal. In addition, the company reports on preliminary results for February which have once again significantly exceeded the record figures from January 2021. In February, NAGA achieved a record user growth with 37,000 new accounts and
Fibocom Announces Multiple Next-Gen 5G NR Modules to 3GPP R16 Standard at MWC Shanghai 20219.3.2021 05:15:00 CET | Press release
Fibocom (Stock Code: 300638), a leading provider of cellular embedded wireless module solutions for the Internet of Things (IoT), announced the world-wide launch of the next generation 5G NR modules compliant with the 3GPP R16 standard during Mobile World Congress Shanghai 2021 (MWCS21). The new launch includes FM160 and FG160 5G module series of Sub-6GHz frequency range, as well as FM160W and FG160W series of mmWave range. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210308005973/en/ Fibocom Next-Gen 5G Modules (Photo: Fibocom) Product video on YouTube: https://www.youtube.com/watch?v=Wg0nE1WtoBM The new 5G NR module series is based on the newly-announced Qualcomm® Snapdragon™ X65 and X62 5G Modem-RF Systems and delivers enhanced mobile broadband and high-reliability, low-latency wireless services for IIoT (Industrial IoT), FWA ( Fixed Wireless Access), 4K/8K live streaming, telemedicine, private 5G networks, and other ma
Solas OLED Wins Patent Infringement Lawsuit Against Samsung9.3.2021 00:04:00 CET | Press release
The following is a statement from Solas OLED Ltd. Solas OLED Ltd. (“Solas”), an Irish company that specializes in patented OLED technologies, today announced that a jury in the U.S. District Court for the Eastern District of Texas has found Samsung Display Co., Ltd., Samsung Electronics Co., Ltd., and Samsung Electronics America, Inc. (collectively “Samsung”) liable to Solas for wilfully infringing two Solas patents, U.S. patent numbers 7,446,338 and 9,256,311. The inventions claimed in these patents are fundamental to OLED displays and are required for AMOLEDs to function; and were or are used prolifically by Samsung in the OLED displays of Galaxy S and Galaxy Note smartphones. After a five-day trial, the jury awarded Solas $62,738,543 in damages for infringement of the two patents. Solas also has cases pending against Samsung before the International Trade Commission and against Samsung Electronics GmbH in the Düsseldorf District Court in Germany. Gerald Padian, co-founder and Direct
Statement on International Women’s Day 2021 by Julia Simon, Chief Legal and Diversity Officer of Mary Kay Inc.8.3.2021 23:00:00 CET | Press release
Below is a statement by Julia Simon, Chief Legal Officer and Chief Diversity Officer, Mary Kay Inc., on International Women’s Day 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210308005888/en/ Julia Simon, Chief Legal Officer and Chief Diversity Officer (Photo: Mary Kay Inc.) Empowered women empower women. This belief serves as the foundation on which all work, internally and externally, rests at Mary Kay Inc. This mantra inspires Mary Kay’s tireless efforts to hire and promote women in leadership positions, support the Women’s Empowerment Principles established by UN Women and UN Global Compact, and develop entrepreneurship and economic opportunities to increase women’s participation and combat gender bias everywhere. If we lift one, we lift all. On International Women’s Day (IWD) 2021 that message rings especially poignant. The theme of this year’s IWD is “Women in leadership: Achieving an equal future in a COVID-19